Factor II Mutation Screening F2 – G20210A Test
Test Name: FACTOR II Mutation Screening F2 – G20210A Test
Components: EDTA Vacutainer (2ml)
Price: 1200.0 AED
Sample Condition: Peripheral blood
Report Delivery: 3-4 days
Method: End Point PCR + RFLP
Test Type: Genetics
Doctor: Oncology
Test Department: Pre Test Information
FACTOR II Mutation Screening (F2 – G20210A) can be done with a doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.
Test Details
Factor II mutation screening, also known as F2 – G20210A mutation screening, is a genetic test that checks for a specific mutation in the Factor II gene. This mutation, known as the G20210A mutation, is associated with an increased risk of developing blood clots, particularly in the veins (venous thromboembolism).
The Factor II gene provides instructions for making a protein called prothrombin, which plays a crucial role in the blood clotting process. The G20210A mutation involves a change in the DNA sequence of the Factor II gene, resulting in increased levels of prothrombin in the blood. This elevated prothrombin level can lead to an increased tendency for blood clot formation.
Factor II mutation screening is typically performed in individuals with a personal or family history of blood clots, particularly at a young age or in unusual locations. It may also be recommended for individuals with a history of recurrent miscarriages, as the mutation has been associated with an increased risk of pregnancy complications.
The screening test involves analyzing a blood sample for the presence of the G20210A mutation. If the mutation is detected, it can help guide treatment and management decisions, such as the use of blood thinning medications to prevent clot formation.
It is important to note that not all individuals with the Factor II mutation will develop blood clots, and other genetic and environmental factors also play a role in determining an individual’s risk. Therefore, the test results should be interpreted in conjunction with other clinical information to assess an individual’s overall risk of clotting disorders.
| Test Name | FACTOR II Mutation Screening F2 – G20210A Test |
|---|---|
| Components | EDTA Vacutainer (2ml) |
| Price | 1200.0 AED |
| Sample Condition | Peripheral blood |
| Report Delivery | 3-4 days |
| Method | End Point PCR + RFLP |
| Test type | Genetics |
| Doctor | Oncology |
| Test Department: | |
| Pre Test Information | FACTOR II Mutation Screening (F2 – G20210A) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
| Test Details |
Factor II mutation screening, also known as F2 – G20210A mutation screening, is a genetic test that checks for a specific mutation in the Factor II gene. This mutation, known as the G20210A mutation, is associated with an increased risk of developing blood clots, particularly in the veins (venous thromboembolism). The Factor II gene provides instructions for making a protein called prothrombin, which plays a crucial role in the blood clotting process. The G20210A mutation involves a change in the DNA sequence of the Factor II gene, resulting in increased levels of prothrombin in the blood. This elevated prothrombin level can lead to an increased tendency for blood clot formation. Factor II mutation screening is typically performed in individuals with a personal or family history of blood clots, particularly at a young age or in unusual locations. It may also be recommended for individuals with a history of recurrent miscarriages, as the mutation has been associated with an increased risk of pregnancy complications. The screening test involves analyzing a blood sample for the presence of the G20210A mutation. If the mutation is detected, it can help guide treatment and management decisions, such as the use of blood thinning medications to prevent clot formation. It is important to note that not all individuals with the Factor II mutation will develop blood clots, and other genetic and environmental factors also play a role in determining an individual’s risk. Therefore, the test results should be interpreted in conjunction with other clinical information to assess an individual’s overall risk of clotting disorders. |
